Abstract
Correction: Macrophage Migration Inhibitory Factor Inhibits the Migration of Cartilage End Plate-Derived Stem Cells by Reacting with CD74
Highlights
Macrophage migration inhibitory factor (MIF) was first described as a soluble factor that is released by activated Tlymphocytes in 1966
cartilage endplate-derived stem cells (CESCs) were immunophenotyped via flow cytometry in accordance with the immunophenotypic criteria of the International Society for Cellular Therapy [31]
The multipotency of CESCs was evaluated via differentiation into osteogenic (Figure 2 A1, A2), adipogenic (Figure 2 B1, B2) and chondrogenic (Figure 2 C1, C2) lineages over a period of 21 days, which indicated that CESCs were capable of differentiating into osteoblasts, adipocytes and chondroblasts under differentiating conditions in vitro tissue culture
Summary
Macrophage migration inhibitory factor (MIF) was first described as a soluble factor that is released by activated Tlymphocytes in 1966. As an important proinflammatory cytokine, MIF might counter-regulate glucocorticoid effects by activating immune/inflammatory cells and promoting the expression of matrix metalloproteinases, nitric oxide and prostaglandin E2 release [1,2,3], or the release of proinflammatory and inflammatory cytokines [4], such as TNF-a, IL- 1b, IL-2, IL-6, IL-8, IFN-c. Each of those proinflammatory and inflammatory cytokines are involved in the pathogenesis of intervertebral disc (IVD) degeneration [5,6,7,8,9]. We investigate the role of MIF in regulating the migration of CESCs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
